SCHEMBL4882033

SCHEMBL4882033

CC(C)(C)[Si](C)(C)OCCNc1ccc(NC(=O)c2nccnc2C(=O)Nc2ccc(C#N)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.39
TP53 P04637 2/20 0.39
NPC1 O15118 1/20 0.39
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALOX15 P16050 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
NAMPT P43490 1/20 0.37
CYP11B1 P15538 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886038 0.92 KMT2A (0.40) MLYCDMAPTALDH1A1TP53NPC1
SCHEMBL4881556 0.90 MAPT (0.42) MAPTALDH1A1TP53NPC1PKM
SCHEMBL15739737 0.84 CETP (0.44) ALDH1A1GAAKMT2A
SCHEMBL4881687 0.84 SIRT2 (0.37) MLYCDMAPTALDH1A1TP53NPC1
SCHEMBL4881605 0.81 KMT2A (0.43) MAPTALDH1A1TP53NPC1RAB9A
SCHEMBL4710501 0.80 RAB9A (0.42) MAPTALDH1A1TP53NPC1RAB9A
SCHEMBL3621276 0.77 NPC1 (0.44) MAPTNPC1RAB9ASMN1; SMN2TRPV1
SCHEMBL4881302 0.77 KMT2A (0.38) MAPTALDH1A1TP53NPC1PKM
SCHEMBL4880731 0.77 MAPT (0.36) MAPTALDH1A1TP53NPC1PKM
SCHEMBL4875148 0.75 RAB9A (0.41) MAPTALDH1A1TP53NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
EP-1819701-A1 CYCLIC IMINOCARBAMATES AND USE THEREOF Bayer HealthCare AG (DE) 2007-08-22 EP disclosed
WO-2006058630-A1 CYCLIC IMINOCARBAMATES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 MLYCD 1221/4885MAPT 4803/4885ALDH1A1 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.